What is Akermin?
Akermin is a cleantech innovator based at BRDG Park at the Danforth Plant Science Center in St. Louis, MO. The company specializes in integrating enzymes within a proprietary Biocatalyst Delivery System. This advanced system is designed for incorporation into conventional industrial processes, offering energy-efficient and green solutions for carbon dioxide management. Akermin's multi-disciplined approach targets various industrial applications, aiming to provide sustainable alternatives for CO2 handling.
How much funding has Akermin raised?
Akermin has raised a total of $12.6M across 4 funding rounds:
Unspecified
$600K
Unspecified
$6.1M
Unspecified
$4.1M
Debt
$1.8M
Unspecified (2009): $600K, investors not publicly disclosed
Unspecified (2009): $6.1M, investors not publicly disclosed
Unspecified (2010): $4.1M, investors not publicly disclosed
Debt (2013): $1.8M, investors not publicly disclosed
What's next for Akermin?
With a substantial enterprise-level funding context and a recent strategic investment, Akermin is poised for significant scaling and further development of its Biocatalyst Delivery System. The company's focus on cleantech and CO2 management aligns with growing global demand for sustainable industrial practices. Future endeavors will likely involve expanding the application of their technology across diverse industrial sectors and potentially forging new partnerships to accelerate market penetration. This strategic financing provides the capital necessary to advance their research, optimize their proprietary system, and solidify their position in the competitive cleantech landscape.
See full Akermin company page
